| Bristol-Myers Squibb Company (BMY) | |||
|---|---|---|---|
| 54.22 -1.04 (-1.88%) | 01-20 16:00 | ||
| Open: | 54.52 | Pre. Close: | 55.26 |
| High: | 54.908 | Low: | 53.88 |
| Volume: | 10,772,823 | Market Cap: | 110,379(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 64.38  One year: 66.62 |
| Support: | Support1: 52.01 Support2: 43.27 |
| Resistance: | Resistance1: 55.12 Resistance2: 57.04 |
| Pivot: | 55.10 |
| Moving Averages: | MA(5): 55.81 MA(20): 54.95  MA(100): 48.49 MA(250): 50.39 |
| MACD: | MACD(12,26): 1.11 Signal(12,26,9): 1.35 |
| %K %D: | %K(14,3): 66.40 %D(3): 80.49 |
| RSI: | RSI(14): 50.79 |
| 52-Week: | High: 63.33 Low: 42.52 Change(%): -4.9 |
| Average Vol(K): | 3-Month: 15404 10-Days: 12982 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 54.997 - 55.328 | 55.328 - 55.573 |
| Low: | 53.088 - 53.528 | 53.528 - 53.855 |
| Close: | 53.644 - 54.292 | 54.292 - 54.773 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BMY ] has closed above bottom band by 31.9%. Bollinger Bands are 9.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Company profile |
|---|
| Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: New York Stock Exchange | |
| Sector: Healthcare | |
| Industry: Drug Manufacturers - General | |
| Shares Out. (M) | 2040.00 |
| Shares Float (M) | 2030.00 |
| % Held by Insiders | 0.08 |
| % Held by Institutions | 82.00 |
| Shares Short (K) | 36580 |
| Shares Short Prior Month (K) | 33890 |
| Stock Financials | |
|---|---|
| EPS | 2.970 |
| Book Value (p.s.) | 9.110 |
| Profit Margin | 12.57 |
| Operating Margin | 31.57 |
| Return on Assets (ttm) | 9.4 |
| Return on Equity (ttm) | 33.8 |
| Qtrly Rev. Growth | 2.8 |
| Gross Profit (p.s.) | 17.225 |
| Sales Per Share | 23.544 |
| EBITDA (p.s.) | 9.422 |
| Qtrly Earnings Growth | 80.90 |
| Operating Cash Flow (M) | 16620.00 |
| Levered Free Cash Flow (M) | 14720.00 |
| Stock Valuation | |
|---|---|
| PE Ratio | 18.26 |
| PEG Ratio | |
| Price to Book value | 5.95 |
| Price to Sales | 2.30 |
| Price to Cash Flow | 6.66 |
| Stock Dividends | |
|---|---|
| Dividend | 0.630 |
| Dividend Yield | 0.01 |
| Dividend Growth | |
